Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Haanen

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapyAllison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
European Urology Oncology|January 21, 2020
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial DataRoderick de Bruijn, Akhila Wimalasingham, Bernadett Szabados, et al.
Future Oncology (London, England)|April 27, 2019
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)Axel Bex, Johan V van Thienen, Mariette Schrier, et al.
ESMO Open|October 2, 2018
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee surveySusana Banerjee, Urania Dafni, Tamara Allen, et al.
European Urology|May 27, 2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancerThomas Powles, Christian Blank, Simon Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
ESMO Open|October 2, 2018
Report on the status of women occupying leadership roles in oncologyEva Hofstädter-Thalmann, Urania Dafni, Tamara Allen, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomasFarah Succaria, Pia Kvistborg, Julie E Stein, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T Ten Ham, Maartje W Rohaan, Inge Jedema, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapyAllison Betof Warner, Omid Hamid, Krishna Komanduri, et al.
European Urology Oncology|January 21, 2020
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial DataRoderick de Bruijn, Akhila Wimalasingham, Bernadett Szabados, et al.
Future Oncology (London, England)|April 27, 2019
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)Axel Bex, Johan V van Thienen, Mariette Schrier, et al.
ESMO Open|October 2, 2018
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee surveySusana Banerjee, Urania Dafni, Tamara Allen, et al.
European Urology|May 27, 2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancerThomas Powles, Christian Blank, Simon Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
ESMO Open|October 2, 2018
Report on the status of women occupying leadership roles in oncologyEva Hofstädter-Thalmann, Urania Dafni, Tamara Allen, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomasFarah Succaria, Pia Kvistborg, Julie E Stein, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T Ten Ham, Maartje W Rohaan, Inge Jedema, et al.
Pageof 7